Business Context and Reporting Period
Company: Apyx Medical Corporation
Filing Type: Form 8-K (Current Report)
Date: May 21, 2026
Principal Office: Clearwater, Florida
Trading Symbol: APYX (Nasdaq Global Select Market)
This filing reports the publication of new clinical data regarding the company's aesthetic treatments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance.
Material Changes
Clinical Data Publication: On May 21, 2026, the company announced the publication of new clinical data in the Aesthetic Surgery Journal Open Forum. The data highlights a promising approach to improving cellulite and skin laxity, addressing two common aesthetic concerns among women.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the clinical findings. No specific financial guidance, outlook, or risk factors were disclosed within the text of this 8-K.
Investor Verification Checklist
- Review the full text of the press release attached as Exhibit 99.1 for specific clinical trial results.
- Verify the publication details in the Aesthetic Surgery Journal Open Forum.
- Assess the potential commercial impact of the cellulite and skin laxity treatment on future revenue streams.
- Check for any subsequent regulatory filings regarding the approval status of the treatment approach.